Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture

Taylor‐Papadimitriou, Joyce; Peterson, Jerry A.; Arklie, J; Burchell, Joy; Ceriani, R. L.; Bodmer, W F

doi:10.1002/ijc.2910280104

Cited by 548 publications

(168 citation statements)

References 21 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…In 90% of the epithelial ovarian tumors the MUC1 antigen is overexpressed on the cell-surface (98). For an overview of anti-MUC1 Mab trials see Table IV.…”

Section: Muc1mentioning

confidence: 99%

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Oei

Sweep²,

Thomas³

et al. 1992

Int J Oncol

View full text Add to dashboard Cite

Abstract.The prognosis for patients with ovarian cancer is still poor and more effective therapeutic modalities are needed. (Radio)immunotherapy using monoclonal antibodies (Mabs) could be one of these approaches. Here, we review the status of (radio)immunotherapy using Mabs for the treatment of ovarian cancer. The Pubmed database was searched for clinical trials investigating the effect of (radio)immunotherapy in ovarian cancer published until October 1, 2007. Keywords for the search were: ovarian cancer, monoclonal antibodies, CA 125, gp38, HER2, HMFG, MUC1, TAG 72 and VEGF. A total of 44 trials on immunotherapy with unconjugated Mabs, Mab vaccination and (radio)immunotherapy directed towards the antigens CA 125, gp38, HER2, MUC1, TAG 72 or VEGF in patients with ovarian cancer were found, reviewed and discussed. Out of these trials, 23 studied immunotherapy with unconjugated Mabs, 5 vaccination with Mabs and 16 trials studied (radio)immunotherapy. The lack of large randomized prospective trials with Mabs directed to tumor-associated antigens expressed on ovarian cancer cells preclude any firm conclusion on the potential of Mabs use in the treatment of ovarian cancer. Oregovomab, directed against CA 125, and bevacizumab, targeting VEGF, are two unconjugated Mabs closest to clinical introduction for the treatment of ovarian cancer. Vaccination with Mab ACA 125 seems promising but these findings need to be confirmed in controlled randomized trials. Sole RIT should be investigated with the appropriate radionuclide and a Mab with high affinity for the specific tumor-associated antigen in the appropriate patient group to determine whether it may have a therapeutic effect. Additionally, appending (radio)immunotherapy with anti-TAG 72 or anti-MUC1 to other treatment strategies such as chemotherapy could also be a strategy worthwhile investigating. The potential of Mabs to complement current treatment paradigms, is encouraging and may bring a significant improvement to the overall therapeutic outcomes currently being achieved in ovarian cancer. IntroductionOvarian cancer is the fourth leading cause of cancer-related death in women, and accounts for the highest mortality rate of all gynecological malignancies (1). Its poor prognosis is mainly the result of the clinically occult nature of this disease. The peritoneal cavity in which the ovaries are localized provides a perfect environment for undisturbed subclinical growth. Furthermore, early detection is difficult because of the general asymptomatic presentation of the disease (2). In the majority (68%) of the patients, ovarian cancer is diagnosed with at least extensive abdominal spread (3). Standard treatment for advanced stage ovarian cancer is tumor debulking surgery and adjuvant chemotherapy. Although most ovarian cancers are sensitive to platinumbased chemotherapy, the prognosis remains poor. The 5-year INTERNATIONAL JOURNAL OF ONCOLOGY 32: 1145-1157 The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review) Abbreviations: ADCC, anti...

show abstract

“…In 90% of the epithelial ovarian tumors the MUC1 antigen is overexpressed on the cell-surface (98). For an overview of anti-MUC1 Mab trials see Table IV.…”

Section: Muc1mentioning

confidence: 99%

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Oei

Sweep²,

Thomas³

et al. 1992

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…M ucin 1 (MUC1) 3 is a epithelial cell-associated mucin that is developmentally regulated and aberrantly expressed by carcinomas, which makes it an important marker in malignancy (1)(2)(3)(4)(5). This molecule exists as a large extended rod protruding from the apical cell membrane into the lumen of the ducts.…”

mentioning

confidence: 99%

Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred

Mukherjee

Ginardi

Madsen

et al. 2000

The Journal of Immunology

View full text Add to dashboard Cite

Pancreatic cancer is a highly aggressive, treatment refractory cancer and is the fourth leading cause of death in the United States. In humans, 90% of pancreatic adenocarcinomas overexpress altered forms of a tumor-specific Ag, mucin 1 (MUC1; an epithelial mucin glycoprotein), which is a potential target for immunotherapy. We have established a clinically relevant animal model for pancreatic cancer by developing a double transgenic mouse model (called MET) that expresses human MUC1 as self molecule and develops spontaneous tumors of the pancreas. These mice exhibit acinar cell dysplasia at birth, which progresses to microadenomas and acinar cell carcinomas. The tumors express large amounts of underglycosylated MUC1 similar to humans. Tumor-bearing MET mice develop low affinity MUC1-specific CTLs that have no effect on the spontaneously occurring pancreatic tumors in vivo. However, adoptive transfer of these CTLs was able to completely eradicate MUC1-expressing injectable tumors in MUC1 transgenic mice, and these mice developed long-term immunity. These CTLs were MHC class I restricted and recognized peptide epitopes in the immunodominant tandem repeat region of MUC1. The MET mice appropriately mimic the human condition and are an excellent model with which to elucidate the native immune responses that develop during tumor progression and to develop effective antitumor vaccine strategies.

show abstract

“…Unfortunately it has not been possible to humanise SM3 which reacts with a five amino acid epitope exposed through the relative deglycosylation of the cancer cell surface mucin protein as compared with the normal breast cell or benign breast lesion (Taylor-Papadimitriou et al, 1981;Burchell et al, 1987, Burchell andTaylor-Papadimitriou, 1993). This makes it more specific for cancer.…”

Section: Discussionmentioning

confidence: 99%

Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1

et al. 2002

View full text Add to dashboard Cite

In early breast cancer axillary nodes are usually impalpable and over 50% of such patients may have an axillary clearance when no nodes are involved. This work identifies axillary node status by imaging with a Tc-99m radiolabelled anti-Polymorphic Epithelial Mucin, humanised monoclonal antibody (human milk fat globule 1), prior to surgery in 30 patients. Change detection analysis of image data with probability mapping is undertaken. A specificity of 93% and positive predictive value of 92% (both 100% if a second cancer in the axilla with negative nodes is considered) were found. A strategy for combining negative imaging with the sentinel node procedure is presented.

show abstract

Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture

Cited by 548 publications

References 21 publications

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred

Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1

Contact Info

Product

Resources

About